Anjali S. Advani

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Efficacy evaluation of glasedgib Sonic Hedgehog pathway inhibition with or without inotuzumab in B-ALL cells using a new co-culturing system model and a validated chemosensitivity assay

Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.

Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024.

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States

The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Clinical and molecular characteristics of extramedullary acute myeloid leukemias.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.

Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study